Organogenesis Holdings Inc.

NasdaqCM:ORGO Rapport sur les actions

Capitalisation boursière : US$383.1m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Organogenesis Holdings Gestion

Gestion contrôle des critères 2/4

Le PDG Organogenesis Holdings' est Gary Gillheeney, nommé en Jan2014, a un mandat de 10.58 ans. La rémunération annuelle totale est $ 6.24M, composée du salaire de 14.6% et des bonus 85.4%, y compris les actions et options de la société. détient directement 0.63% des actions de la société, d'une valeur de $ 2.26M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.9 ans et 3.8 ans.

Informations clés

Gary Gillheeney

Directeur général

US$6.2m

Rémunération totale

Pourcentage du salaire du PDG14.6%
Durée du mandat du directeur général10.7yrs
Propriété du PDG0.6%
Durée moyenne d'occupation des postes de direction7yrs
Durée moyenne du mandat des membres du conseil d'administration3.8yrs

Mises à jour récentes de la gestion

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Sep 09
Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Jun 10
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis Holdings: What Now

May 18

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

Mar 31
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Mar 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Analyse de la rémunération des PDG

Comment la rémunération de Gary Gillheeney a-t-elle évolué par rapport aux bénéfices de Organogenesis Holdings?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

US$6m

Dec 31 2023US$6mUS$909k

US$5m

Sep 30 2023n/an/a

US$13m

Jun 30 2023n/an/a

US$10m

Mar 31 2023n/an/a

US$13m

Dec 31 2022US$6mUS$883k

US$16m

Sep 30 2022n/an/a

US$59m

Jun 30 2022n/an/a

US$71m

Mar 31 2022n/an/a

US$83m

Dec 31 2021US$4mUS$835k

US$94m

Sep 30 2021n/an/a

US$62m

Jun 30 2021n/an/a

US$69m

Mar 31 2021n/an/a

US$43m

Dec 31 2020US$3mUS$823k

US$17m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$819k

-US$39m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$58m

Dec 31 2018US$3mUS$798k

-US$65m

Sep 30 2018n/an/a

-US$60m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$32m

Dec 31 2017US$1mUS$780k

-US$9m

Rémunération vs marché: La rémunération totale de Gary ($USD 6.24M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.41M ).

Rémunération et revenus: La rémunération de Gary a augmenté alors que l'entreprise n'est pas rentable.


PDG

Gary Gillheeney (69 yo)

10.7yrs

Titularisation

US$6,244,671

Compensation

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Gary Gillheeney
President10.7yrsUS$6.24m0.63%
$ 2.4m
David Francisco
Chief Financial Officer3.6yrsUS$1.63m0.048%
$ 184.5k
Patrick Bilbo
Chief Operating Officer7yrsUS$2.16m0.26%
$ 1.0m
Lori Freedman
Chief Administrative & Legal Officer7.7yrsUS$1.99m0.063%
$ 242.5k
Brian Grow
Chief Commercial Officer7yrsUS$1.92m0.078%
$ 300.0k
William Kolb
Secretaryno datapas de donnéespas de données
Robert Cavorsi
Vice President of Strategy3.7yrspas de données0.11%
$ 403.9k

7.0yrs

Durée moyenne de l'emploi

57.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ORGO est chevronnée et expérimentée (ancienneté moyenne 6.9 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Gary Gillheeney
President5.8yrsUS$6.24m0.63%
$ 2.4m
Glenn Nussdorf
Director21.7yrspas de données11.29%
$ 43.2m
Alan Ades
Director21.7yrspas de données11.5%
$ 44.1m
Arthur Leibowitz
Lead Independent Director5.8yrsUS$291.46k0.10%
$ 394.8k
Robert Ades
Director3.8yrspas de donnéespas de données
Jon Giacomin
Independent Director3.3yrsUS$265.00k0.068%
$ 259.6k
Michele Korfin
Independent Director2.3yrsUS$226.98k0.068%
$ 259.1k
Prathyusha Duraibabu
Independent Director2.8yrsUS$240.00k0.071%
$ 271.2k
David Erani
Director3.8yrspas de donnéespas de données
Michael Driscoll
Independent Director2.6yrsUS$230.52kpas de données
Gilberto Quintero
Independent Director2.3yrsUS$226.98k0.068%
$ 259.1k

3.8yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ORGO sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).